表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）的问世开启了 EGFR 突变非小细胞肺癌（NSCLC）的精准治疗时代，特别是三代 EGFR-TKI 奥希替尼，凭借着显著的全身和颅内疗效获益，已成为此类患者的一线标准治疗方案[1-3]。然而，EGFR-TKI 单药治疗存在一定的局限性，比如存在 EGFR L858R ...

表皮生长因子受体（EGFR）突变非小细胞肺癌（NSCLC）具有高度异质性，EGFR 突变类型、共突变状态、肿瘤负荷等均可能影响其靶向治疗效果。FLAURA2 研究最终总生存期（OS）数据显示，一线奥希替尼联合化疗可显著延长 EGFR 突变晚期 ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...

The FDA accepted an application for ivonescimab with chemotherapy for patients with lung cancer driven by EGFR changes after ...

In a media release on Jan. 22, it was revealed that a group of scientists from the Agency for Science, Technology and ...

The FDA accepted the BLA for ivonescimab plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer post-TKI ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...

The APPLE trial began recruitment in November 2017 and ended in February 2020 (5). It was a randomised, open-label, non-comparative, multicentre, phase II study which enrolled treatment naïve patients ...